{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:36:04Z","timestamp":1792805764229,"version":"4.5.0"},"reference-count":34,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>RNA interference (RNAi) represents a novel approach for alternative antiviral therapy. However, issues related to RNA delivery and stability have presented serious obstacles for obtaining good therapeutic efficacy. Viral vectors are capable of efficient delivery of RNAi as short interfering RNA (siRNA), short hairpin RNA (shRNA) and micro-RNA (miRNA). Efficacy in gene silencing for therapeutic applications against viral diseases has been demonstrated in various animal models. Rotavirus (RV) miR-7 can inhibit rotavirus replication by targeting the RV nonstructural protein 5. Viral gene silencing by targeting the RNAi pathway showed efficient suppression of hepatitis B virus replication by adeno-associated virus (AAV)-based delivery of RNAi hepatitis B virus (HBV) cassettes. Hepatitis C virus replication has been targeted by short hairpin RNA molecules expressed from lentivirus vectors. Potentially, RNAi-based approaches could be suitable for antiviral drugs against COVID-19.<\/jats:p>","DOI":"10.3390\/v12101189","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T09:28:23Z","timestamp":1603186103000},"page":"1189","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Are Viral Vectors Any Good for RNAi Antiviral Therapy?"],"prefix":"10.3390","volume":"12","author":[{"given":"Kenneth","family":"Lundstrom","sequence":"first","affiliation":[{"name":"PanTherapeutics, Route de Lavaux 49, CH1095 Lutry, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Lundstrom, K. (2020). Coronavirus Pandemic\u2014Therapy and Vaccines. Biomedicines, 8.","DOI":"10.3390\/biomedicines8050109"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1126\/science.1065329","article-title":"An extensive class of small RNAs in Caenorhabditis elegans","volume":"294","author":"Lee","year":"2001","journal-title":"Science"},{"key":"ref_3","first-page":"141","article-title":"Short hairpin RNA (shRNA): Design, delivery and assessment of gene knockdown","volume":"629","author":"Moore","year":"2010","journal-title":"Methods Mol. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Lundstrom, K. (2020). Self-amplifying RNA viruses as RNA vaccines. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21145130"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Lundstrom, K. (2020). Viral Vectors Applied for RNAi-based Antiviral Therapy. Viruses, 12.","DOI":"10.3390\/v12090924"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Chen, L., Du, J., Hu, X., Xie, Y., Wu, J., Lin, X., Yin, N., Sun, M., and Li, H. (2020). MicroRNA-7 Inhibits Rotavirus Replication by Targeting Viral NSP5 In Vivo and In Vitro. Viruses, 12.","DOI":"10.3390\/v12020209"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Van den Berg, F., Limani, S.W., Mnyandu, N., Maepa, M.B., Ely, A., and Arbuthnot, P. (2020). Advances with RNAi-based Therapy for Hepatitis B Virus Infection. Viruses, 12.","DOI":"10.3390\/v12080851"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Elbadawy, H.M., Abdul, M.I., Aljuhanii, N., Vittiello, A., Ciccarese, F., Abouzied, M.M., Shehata, A.M., Shaker, M.A., Eltahir, E.M., and Palu, G. (2020). Generation of combinatorial lentiviral vectors expressing multiple anti-hepatitis C virus shRNAs and their validation on a novel HCV replicon double reporter cell line. Viruses, 12.","DOI":"10.3390\/v12091044"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1128\/JVI.79.3.1645-1654.2005","article-title":"Computational design of antiviral RNA interference strategies that resist human immunodeficiency virus escape","volume":"79","author":"Leonard","year":"2005","journal-title":"J. Virol."},{"key":"ref_10","unstructured":"(2020, October 13). HIVsirDB. Available online: http:\/\/crdd.osdd.net\/raghava\/hivsir."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.bbrc.2004.02.157","article-title":"An algorithm for selection of functional siRNA sequences","volume":"316","author":"Amarzguioui","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.2174\/1381612043382675","article-title":"Three properties of the hepatitis C virus RNA genome related to antiviral strategies based on RNA-therapeutics: Variability, structural conformation and tRNA mimicry","volume":"10","author":"Gomez","year":"2004","journal-title":"Curr. Pharm. Des."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10555-017-9717-6","article-title":"RNA interference-based therapy and delivery systems","volume":"37","author":"Chen","year":"2018","journal-title":"Cancer Metastasis Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"28912","DOI":"10.3390\/ijms161226142","article-title":"Cell Penetrating peptide conjugated chitosan for enhanced delivery of nucleic acid","volume":"16","author":"Layek","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.ymthe.2017.03.021","article-title":"Functional delivery of lipid-conjugated siRNA by extracellular vesicles","volume":"25","author":"Mager","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: Overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"ref_17","first-page":"119","article-title":"Influence of Pre-existing Anti-Capsid Neutralizing and Binding Antibodies on AAV Vector Transduction","volume":"9","author":"Fitzpatrick","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1525-0016(02)00056-4","article-title":"Novel Semliki Forest virus vectors with reduced cytotoxicity and temperature sensitivity for long-term enhancement of transgene expression","volume":"7","author":"Lundstrom","year":"2003","journal-title":"Mol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/jgm.1078","article-title":"Lentiviral vectors that carry anti-HIV shRNAs: Problems and solutions","volume":"9","author":"Berkhout","year":"2007","journal-title":"J. Gene Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.meegid.2017.08.001","article-title":"Significant inhibition of Tembusu virus envelope and NS5 gene using an adenovirus-mediated short hairpin RNA delivery system","volume":"54","author":"Wang","year":"2017","journal-title":"Infect. Genet. Evol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.antiviral.2012.10.008","article-title":"An adenoviral vector-based expression and delivery system for the inhibition of wild-type adenovirus replication by artificial miRNAs","volume":"97","author":"Ibrisimovic","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2174\/2211536611201010019","article-title":"Efficient silencing of hepatis B by helper-dependent adenovirus vector-mediated delivery of artificial antiviral primary micro RNAs","volume":"1","author":"Mowa","year":"2012","journal-title":"Microrna"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/978-1-4939-3271-9_10","article-title":"Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids","volume":"1382","author":"Castle","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.omtn.2017.04.007","article-title":"Sustained Inhibition of HBV Replication In Vivo after Systemic Injection of AAVs Encoding Artificial Antiviral Primary MicroRNAs","volume":"7","author":"Maepa","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1128\/JVI.01940-12","article-title":"Attenuation of Semliki Forest virus neurovirulence by microRNA-mediated detargeting","volume":"87","author":"Ylosmaki","year":"2013","journal-title":"J. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"10637","DOI":"10.1128\/JVI.01868-15","article-title":"MicroRNA-attenuated clone of virulent Semliki Forest virus overcomes antiviral type I interferon in resistant mouse CT-2A glioma","volume":"89","author":"Martikainen","year":"2015","journal-title":"J. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1158\/1078-0432.CCR-16-0925","article-title":"Safe and effective treatment of experimental neuroblastoma and glioblastoma using systemically delivered triple microRNA-detargeted Oncolytic Semliki forest virus","volume":"23","author":"Ramachandran","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2174\/1381612823666171109112307","article-title":"Design and delivery of therapeutic siRNAs: Application of MERS-Coronavirus","volume":"24","author":"Sohrab","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s11262-019-01701-y","article-title":"Short hairpin RNAs targeting M and N genes reduce replication of porcine deltacoronavirus in ST cells","volume":"55","author":"Gu","year":"2019","journal-title":"Virus Genes"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s12250-020-00221-6","article-title":"Computational identification of small RNA targets in SARS-CoV-2","volume":"35","author":"Chen","year":"2020","journal-title":"Virol. Sin."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.2217\/epi-2020-0162","article-title":"Potential use of noncoding RNAs and innovative therapeutic strategies to target the 5\u2019UTR of SARS-CoV-2","volume":"12","author":"Baldassarre","year":"2020","journal-title":"Epigenomics"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.biotechadv.2019.04.012","article-title":"RNAi Therapeutic and Its Innovative Biotechnological Evolution","volume":"37","author":"Weng","year":"2019","journal-title":"Biotechnol. Adv."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/emmm.200900023","article-title":"RNAi-based therapeutics-current status, challenges and prospects","volume":"1","author":"Tiemann","year":"2009","journal-title":"EMBO Mol. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1261\/rna.25706","article-title":"Widespread siRNA \u2018off-target\u2019 transcript silencing mediated by seed region sequence complementarity","volume":"12","author":"Jackson","year":"2006","journal-title":"RNA"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/12\/10\/1189\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:24:34Z","timestamp":1760178274000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/12\/10\/1189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,20]]},"references-count":34,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["v12101189"],"URL":"https:\/\/doi.org\/10.3390\/v12101189","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,20]]}}}